Glenmark PharmaceuticalsNSE:GLENMARK +1.96%85 Gross Margin % is 68.82% as of Mar. 2026, which is 12% above its 10-year median of 61.52. GuruFocus rates NSE:GLENMARK with a GF Score™ of 85/100 and a GF Value™ of ₹1,985.68 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 938 Drug Manufacturers companies, Glenmark Pharmaceuticals ranks better than 83.69% on this metric.
NSE:GLENMARK's Gross Margin % is ranked better than 83.69% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:GLENMARK: 71.59
Glenmark Pharmaceuticals had a gross margin of 68.82% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Glenmark Pharmaceuticals had a gross margin of 68.82% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Glenmark Pharmaceuticals Gross Margin % Related Terms
Glenmark Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLENMARK vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glenmark Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Glenmark Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Gross Margin % of 68.82% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Glenmark Pharmaceuticals and its competitors. This is 12% above median its historical median of 61.52. Over the past decade, Glenmark Pharmaceuticals' Gross Margin % has ranged from 58.07 to 71.59. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #153 out of 938 companies in the Drug Manufacturers industry, placing it in the top 16.3%.
Is Glenmark Pharmaceuticals' Gross Margin % too high?
Glenmark Pharmaceuticals' current Gross Margin % of 68.82% is 12% above median its 10-year median of 61.52. Over the past 10 years, this metric has ranged from a low of 58.07 to a high of 71.59. The Drug Manufacturers industry median Gross Margin % is 48.54. Glenmark Pharmaceuticals' value of 68.82% is 41.8% above this industry median. Based on the distribution chart, Glenmark Pharmaceuticals ranks #153 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #153 out of 938 companies for Gross Margin %. This places Glenmark Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Glenmark Pharmaceuticals' value of 68.82% is 41.8% above this benchmark. Historically, Glenmark Pharmaceuticals' own Gross Margin % has ranged from 58.07 to 71.59 over the past decade. While the company's 10-year median is 61.52 vs. the industry median of 48.54, Glenmark Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glenmark Pharmaceuticals's current Gross Margin % of 68.82% is 41.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Glenmark Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current Gross Margin % is 68.82%, which is 12% above median its own 10-year median of 61.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,985.68, compared to a current price of ₹2,267.20 — trading 14.2% above its estimated fair value. The current Gross Margin % is 68.82%, which is 12% above median its 10-year median of 61.52 and 41.8% above the Drug Manufacturers industry median of 48.54. Glenmark Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Gross Margin % is 68.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,267.20 is trading 14.2% above its estimated GF Value™ of ₹1,985.68.
GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for NSE:GLENMARK:
Gross Margin %: 68.82% (12% above median its 10-year median of 61.52)
GF Value™: ₹1,985.68 vs. price of ₹2,267.20 (14.2% above fair value)
Industry Position: 41.8% above the Drug Manufacturers median (#153 of 938)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score
Get the complete analysis for NSE:GLENMARK
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
